SU_5402_COA_15218_MedChemExpress
Gelucire-14-44-SDS-MedChemExpress
Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:Nov.-23-2018Print Date:Nov.-23-20181. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :Gelucire 14/44Catalog No. :HY-Y1892CAS No. :121548-04-71.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:NoneFormula:N/AMolecular Weight:N/ACAS No. :121548-04-74. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Pure form-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance White to off-white (Oil)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2018 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
26291346_基于UPLC-MS
Abstract: A UPLC-MS/MS method was established to quantitatively determine the content of alliin in animal plasma to study whether alliin and alliin in garlic enteric preparations can react to produce the active ingredient allicin in the in vivo environment. Methods Reversed-phase C18 column (Waters ICQUITY UPLC BEH, 100 × 2.1 mm, 1.7μm), column temperature: 40 ℃, flow rate: 0.15 mL/min, injection volume: 2μl, Mobile phase: 0.1% formic acid (A)-acetonitrile (B), gradient elution; mass spectrometry ionization: ESI+, determination of allicin in rat plasma . Results The results of two parallel experiments of garlic enteric preparation and enzymatic garlic powder showed that in the garlic enteric preparation with allinase, the plasma concentration of alliin in the blood of rats was significantly lower. Conclusion A UPLC-MS/MS method for the quantitative determination of alliin in animal plasma has been established. Alliin and alliin in garlic enteric-coated preparations can react in vivo.Key words: Garlic enteric preparation; garbonine; UPLC-MS-MS基于UPLC-MS/MS大蒜肠溶制剂中蒜氨酸、蒜酶体内反应情况研究杨亮1，胡小霞4 ，宋百灵4，关明3，李新霞2*（1.新疆警察学院 新疆 乌鲁木齐 8300112.新疆医科大学药学院 新疆 乌鲁木齐 8300113.新疆师范大学化学化工学院 新疆 乌鲁木齐 8300544.新疆医科大学中心实验室 新疆 乌鲁木齐 830011）Study on the Reaction of Garlic and Uterine in the UPLC-MS / MS of Garlic SausolYANG Liang 1，HU Xiaoxia 4 ，SONG Bailing 4，GUAN Ming 3，LI Xinxia 2*(1. Xinjiang Police College, Urumqi 830054, Xinjiang China2.Chemistry and Chemical Engineering of Xinjiang Normal University College, Urumqi 830054, Xinjiang China3.School of Pharmacy, Xinjiang Medical University, Urumqi 830011, Xinjiang China4.Central Laboratory of Xinjiang Medical University, Urumqi 830011, Xinjiang China ）摘要：目的 建立定量测定动物血浆中蒜氨酸含量的UPLC-MS/MS 方法，研究大蒜肠溶制剂中蒜氨酸、蒜酶能否在体内环境下反应生成活性成分大蒜辣素。
Pimecrolimus_SDS_MedChemExpress
Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:May-24-2017Print Date:May-24-20171. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :PimecrolimusCatalog No. :HY-13723CAS No. :137071-32-01.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureGHS Classification in accordance with 29 CFR 1910 (OSHA HCS)Acute toxicity, Oral (Category 4),H302Acute aquatic toxicity (Category 1),H400Chronic aquatic toxicity (Category 1),H4102.2 GHS Label elements, including precautionary statementsPictogramSignal word WarningHazard statement(s)H302 Harmful if swallowed.H410 Very toxic to aquatic life with long lasting effects.Precautionary statement(s)P264 Wash skin thoroughly after handling.P270 Do not eat, drink or smoke when using this product.P273 Avoid release to the environment.P301 + P312 IF SWALLOWED: Call a POISON CENTER or doctor/ physician if you feel unwell.P330 Rinse mouth.P391 Collect spillage.P501 Dispose of contents/ container to an approved waste disposal plant.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:SDZ⁻ASM 981Formula:C43H68ClNO11Molecular Weight:810.45CAS No. :137071-32-04. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Powder-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance White to off-white (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGUN number: 3077Class: 9Packing group: IIIEMS-No: F-A, S-FProper shipping name: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.Marine pollutant: Marine pollutant.IATAUN number: 3077Class: 9Packing group: IIIProper shipping name: Environmentally hazardous substance, solid, n.o.s.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2017 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
亲和超滤技术快速发现中药中抗炎成分的方法学_吴新安
# 759#
亲和超滤技术快速发现中药中抗炎成分的方法学
吴新安1, 付贵峰 1, 朱 捷 1, 于能江2
摘要 目的 建立一 种生物 亲和超 滤方法 解决抗 炎活性 物 质快速筛选的问题。 方法 利 用生物 亲和超 滤技 术设计 以 COX2酶为靶酶, 在中草药提 取物 中添加 COX 2酶 抑制剂 塞 来昔布进行筛选, 以格列 吡嗪作 为对照, 结合 H PLC-DAD 和 HPLC-M S 技术进行快速分离和检测。结 果 成 功筛选 到目 标化合物塞来昔布。 结论 亲 和超滤 与液质 联用 技术是 快 速、简便、高效、灵敏、成本相对较低的筛 选模式。 主题词 中草药 /化学 自由词 亲和超滤; COX 2酶; 抗炎活性成分; 塞来昔布 中图分类号 R 282. 71; R 284. 1; R 345 文献标识码 A 文章编号 1000- 1492( 2011) 08- 0759- 04
7 50
Ñ
52. 4
uc
3 20 A ( 125. 0) 916. 3 1 500
Ñ 225. 6
uc
4 20 A ( 187. 5) 1 374. 4 2 250
Ñ 240. 5
uc
5 20 A ( 250. 0) 1 832. 5 3 000
Ñ 450. 0) 916. 3
图 2 样品 3超滤后 LC-DAD色谱 1: 塞来昔布
图 3 样品 3超滤后 LC-MS总离子流色谱 1: 塞来昔布
图 4 样品 3 超滤后选择性离子 L C-M S色谱 1: 塞来昔布
11007X - 41923, r= 01999 8, X = 52 ~ 416 ng。随后 对样品 1~ 5进行了筛选分析, 图 2为样品 3筛选分 析后加酶试验组 与不加酶对照组的 HPLC-DAD 图 谱的叠合图, 图 3 为样 品 3 筛选 分析 后的 H PLC( - ) ESIM S总离子 流图谱的叠合图谱。结 果表明 H PLC-DAD 和 H PLC-( - ) ESIM S 都显 著检测 到了 各样品中的塞来昔布。图 1中列出了样品 1~ 5筛 选检出的塞来昔布的量, 结果表明随着加入样品浓 度的增加, 检出量也明显随着增加。说明 COX-2用 量为 972 pm ol时, H PLC-DAD 与 HPLC-( - ) ESIM S 一样具备足够的灵敏度用于检测被筛选出的塞来昔 布。另外, 在 ( - ) ESIM S检测中将离子检测范围限 定在 塞 来 昔 布 的 负 准 分 子 离 子 范 围 内 ( 380 ~ 38015) 时, 最小检出限得到大幅降低, 见图 4。因而 若被筛选化合物组合库中各化合物的分子量已知, 利用限定离子检测范围的方法将大幅提高检测出能 力从而提高方法的准确性。结果还显示在 5个样品 的筛选检测结果中均未检测到阴性药格列吡嗪, 见 表 1、图 2, 初步表明该筛选方法对于 COX 抑制剂具 有较好的选择性。结果提示该方法不但能够筛选出 COX-2抑制剂, 而且能够有效避免假阳性结果, 筛选 的准确性很高。 2. 2 中草药成分对筛选方法的干扰 实验中将 2 份与样品 3含量相同的塞来昔布溶液分别加入到 2 份浓度分别为塞来昔布的浓度的 45倍和 227倍的 八味地黄提取物溶液中, 见表 1中样品 6、7, 然后进 行筛选。结果显示八味地黄提取物的量为塞来昔布 的 227 倍时, 仍不影响利用亲和超滤和 H PLC-DAD 筛选和检出塞来昔布, 见图 5, 说明八味地黄提取物 基本不影响塞来昔布与 COX-2的 特异性结合和解 离, 而且对 HPLC-DAD 检出塞来昔布干扰很小。但 八味地黄提取物的含 量仅为塞来昔 布的 45倍 时, H PLC-( - ) ESIM S 就几乎检测不出塞来昔布, 见图 6。对离子检测范围进行限定后成功地检出了塞来 昔布, 见图 7。说明 八味 地 黄提 取 物中 的 成分 对 H PLC-( - ) ESIM S 检出塞来昔布干扰较大, 要排除
哌啶酸检测
迪信泰检测平台
哌啶酸检测
哌啶酸（Pipecolic acid），又称2-哌啶甲酸，是一种重要的刚性环状非蛋白质氨基酸，它既可以限定多肽的构象，还可作为不同化合物合成库中的多功能骨架，所以广泛用于许多手性药物和生物活性物质的制备。
哌啶酸的合成方法主要分为生物催化合成、化学不对称合成和光催化合成。
迪信泰检测平台采用液相质谱联用(LC-MS)的方法，使用Thermo Scientific的
U3000快速液相色谱对样品进行分离，Thermo Scientific™ Q Exactive™对样品进行鉴定，可高效、精准的检测哌啶酸的含量变化。
此外，我们还提供其他极性小分子系列检测服务，以满足您的不同需求。
LC-MS测定哌啶酸样本要求：
1. 请确保样本量大于0.2g或者0.2mL。
周期：2~3周。
项目结束后迪信泰检测平台将会提供详细中英文双语技术报告，报告包括：
1. 实验步骤（中英文）。
2. 相关参数（中英文）。
3.质谱图片。
4. 原始数据。
5. 哌啶酸含量信息。
迪信泰检测平台可根据需求定制其他物质测定方案，具体可免费咨询技术支持。
Keap1
非小细胞肺癌(non-small cell lung cancer，NSCLC)发病率占据肺癌的75%~80%。
肿瘤细胞进展快且易扩散转移，临床常采用手术、放化疗等进行治疗，但5年生存率低于60%[1-2]。
氧化应激是由活性氧(ROS)生成量增加所致，ROS积累可诱导肺癌细胞凋亡，清除ROS 可阻止癌细胞凋亡，即肺癌细胞存活依赖于癌细胞自身抗氧化能力[3]。
Kelch样环氧氯丙烷相关蛋白-1 (kelch-like epichlorohydrin-associated protein-1，Keap1)/核因子E2相关因子2(nuclear factor E2related factor 2，Nrf2)信号通路在癌症中发挥重要调控作用，氧化应激可激活Keap1，促使Keap1-Nrf2复合物裂解，Nrf2转移至细胞核内，可激活下游靶基因表达，参与肺癌发生发展过程[4]。
Nrf2可维持氧化还原稳态，ROS侵袭细胞时，Nrf2可进入细胞核，结合抗氧化反应元件(ARE)转录编码各种抗氧化蛋白、代谢酶基因，抑制氧化应激反应[5-6]。
目前氧化应激、Keap1/Nrf2信号通路在NSCLC发生过程中的机制尚未明确。
基于此，本研究尝试分析Keap1/Nrf2信号通路与临床病理参数、氧化应激指标的相关性，探讨其在NSCLC氧化应激机制中的作用，为临床研制新药提供参考依据。
1资料与方法1.1一般资料选取2017年4月至2020年4月郑州市第三人民医院收治的100例NSCLC患者为研究对象。
纳入标准：符合NSCLC诊断标准[7]；术前未接受放化疗、免疫治疗者；预计生存期≥6个月；符合手术适应证、禁忌证；Karnofsky功能状态评分≥70分；签署知情同意书。
排除标准：合并凝血功能障碍、肝肾功能障碍、其他恶性肿瘤者；伴有急/慢性感染者；伴有精神疾病者；既往腹部相关外科手术史者。
所有患者均行肺癌根治性切除术，术中收集癌组织、癌旁组织(距离癌组织5cm范围内正常组织)，其中男性63例，女性37例；年龄46~67岁，平均(56.32±3.16)岁；体质量指数(BMI)17~30kg/m2，平均(23.16±2.03)kg/m2；病理类型：鳞癌58例、腺癌42例；病理分级[8]：Ⅰ~Ⅱ级51例、Ⅲ级49例；T分期[9]：T1~T253例、T3~T447例；N分期：N055例、N1~N245例。
致病疫霉菌效应蛋白Pi05440毒性功能验证及寄主候选靶标筛选
核农学报2024，38（3）：0434~0442Journal of Nuclear Agricultural Sciences致病疫霉菌效应蛋白Pi05440毒性功能验证及寄主候选靶标筛选张蝶陈胜男赵迪王荟洁王洪洋 *刘晶 *（云南师范大学，云南省马铃薯生物学重点实验室，云南昆明650500）摘要：致病疫霉菌（Phytophthora infestans）侵染时会分泌大量效应蛋白进入寄主细胞，通过操纵寄主靶标抑制植物免疫反应。
为研究致病疫霉菌效应蛋白Pi05440的功能，本研究重点分析了Pi05440的蛋白特征、毒性功能及鉴定其寄主靶标；利用生物信息学数据库，预测Pi05440的保守结构域和信号肽。
构建pRI101-GFP-Pi05440表达载体用于Pi05440的亚细胞定位和毒性功能分析；同时，利用酵母双杂交技术对Pi05440的寄主靶标蛋白进行了筛选和鉴定。
结果表明，Pi05440基因全长969 bp，编码322个氨基酸。
结构预测结果显示Pi05440含有3个典型的KAZAL功能域。
亚细胞定位结果表明Pi05440定位在质膜和细胞间隙。
在本氏烟中瞬时表达该基因显著促进致病疫霉菌扩展。
通过酵母双杂交筛选，初步鉴定到3个Pi05440的候选靶标蛋白，分别为马铃薯过氧化氢酶12、马铃薯几丁质酶以及马铃薯MYB-like A蛋白。
本研究为探究致病疫霉菌效应蛋白Pi05440及其靶标蛋白如何调控植物免疫提供了重要线索。
关键词：致病疫霉菌；效应蛋白；亚细胞定位；酵母双杂交；靶标蛋白DOI：10.11869/j.issn.1000‑8551.2024.03.0434马铃薯（Solanum tuberosum）富含碳水化合物、维生素、矿物质和抗氧化物质等营养成分，对人类健康和可持续农业发展至关重要［1］。
然而，马铃薯生产过程中会面临许多病害的威胁，其中最为严重的是由致病疫霉菌（Phytophthora infestans）引起的晚疫病。
211232354_华蟾酥毒基通过调控circNFIX
华蟾酥毒基通过调控circNFIX/miR -577通路抑制乳腺癌MDA -MB -231 细胞的增殖、迁移和侵袭何孙香 吴中伟① 刘梅芬 （九江市中医医院肿瘤科，九江 339000）中图分类号 R282.74 R737.9 文献标志码 A 文章编号 1000-484X （2023）04-0770-07［摘要］ 目的：研究华蟾酥毒基（CnBu ）对乳腺癌细胞MDA -MB -231恶性生物学行为的影响，并探讨其机制是否与调控环状RNA 核因子IX （circNFIX ）和miR -577表达相关。
方法：将MDA -MB -231细胞分为对照（Con ）组、CnBu -低剂量（L ）组、 CnBu -中剂量（M ）组、CnBu -高剂量（H ）组、si -NC 组、si -circNFIX 组、pcDNA 组、pcDNA -circNFIX 组、CnBu+pcDNA 组、CnBu+pcDNA -circNFIX 组。
MTT 、Transwell 实验分析细胞增殖、迁移和侵袭能力，Western blot 分析Ki -67、基质金属蛋白酶2（MMP -2）和MMP -9蛋白表达。
RT -qPCR 分析circNFIX 、miR -577表达量。
双荧光素酶报告实验和RT -qPCR 验证circNFIX 和miR -577的靶向调控关系。
结果：CnBu 以剂量依赖方式下调Ki -67、MMP -2、MMP -9蛋白和circNFIX 表达（P <0.05），上调miR -577表达（P <0.05），减弱MDA -MB -231细胞的增殖、迁移和侵袭能力（P <0.05）。
miR -577与circNFIX 序列直接结合，干扰或过表达circNFIX 可显著提高或降低miR -577表达水平（P <0.05）。
干扰circNFIX 表达显著下调Ki -67、MMP -2、MMP -9蛋白表达（P <0.05），减弱MDA -MB -231细胞的增殖、迁移和侵袭能力（P <0.05）。
白刺链霉菌15-4-2中的抗MRSA活性成分研究
１ 材料 ． １ １ ． 放线菌菌株 ．１ １ 白刺 链 霉 菌 １ － — 由 中 国热 带 农 业 科 学 院 热 带 ４２ ５
生 物 技 术研 究所 曾会 才 研 究员 课 题 组 白海 南 省 霸 王 岭 热 带 原 始 林 区 的 土 壤 中 分 离 获 得 。将 本 菌 株 １ ｓ ６ ｒ ＤＮＡ序 列提 交 至 Ｇｅ Ｂａ ｋ ｌｓ分析 ，在 系 统发 育 ｎ ｎ 做ｂａｔ
Ｄｅ ｅｏ ｍｅ ｔ ｆ ｏ ｉａ ｔｒ ｌ ｒ ｄ ｃｓ Ｈａｋ ｕ５ １ １ ｖ ｌｐ ｎ Ｔｒｐｃ ｌ ｏ Ｎａｕ ａ ｏ ｕ ｔ， ｉｏ ７１ ） Ｐ ｏ
Ａｂ ｔａ ｔ Ｏｂ ｅ ｔ ｅ Ｔ ｔｄ ｈ ｎｉａ ｔｒ ｌｃ ｎ ｔ ｕ ｎ ｓｆｏ ｔｅ ｆｒ ｎ ａｉｎ ｂ ｏｈ ｏ ｔｅ ｔｍｙ ｅ ｓｒ ｃ ｊ ｃｉ ｏ ｓ ｙ ｔ ｅａ ｔ ｃｅｉ ｏ ｓｉ ｅ ｔ ｒ ｍ ｈ ｅｍｅ ｔｔｏ ｒ ｔ ｆ ｒｐ ｏ ｃ ｓ ｖ ｕ ｂ ａ ｔ Ｓ
链 霉 菌是具 有复杂 生活 周期 的革兰 阳性放 线菌 ， 链 霉 菌 属 的许 多成 员 都 能 产 生在 医疗 、农 业 、食 品
药物 ，其 具 有广 谱 的抗菌 活 性ｆ。 四环类 抗 生素 如 四 ２ ］
环 素 、 金霉 素和 大 环 内酯 类 抗 生 素如 红 霉 素 也 是 放
活 性 筛选 的过 程 中 ，发现 白刺 链 霉 菌（ ｔｅ ｔｍｙ ｅ Ｓｒｐ ｏ ｃ ｓ ａｂ ｓ ｉｕ ） ５４ ２ 发酵 液 显 示 出抗 ＭＲＳ ｌｏｐ ｎ ｓ １ －— 的 Ａ活性 。本 文 对 从该 菌 的发酵 液 中分 离得 到７个 化合 物及 其体 外 抗 菌 活性 测试 结 果进 行报 道 。
中 国抗 生 素 杂 志 ２ １年 ２ ０ ２ 月第 ３ 卷 第 ２ ７ 期
非布司他的新晶型及其制备方法[发明专利]
![非布司他的新晶型及其制备方法[发明专利]](https://img.taocdn.com/s3/m/c14369ca192e45361166f548.png)
专利名称：非布司他的新晶型及其制备方法
专利类型：发明专利
发明人：周兴国,唐雪民,邓杰,叶文润,罗杰,张道临,樊斌申请号：CN200610095263.0
申请日：20061207
公开号：CN1970547A
公开日：
20070530
专利内容由知识产权出版社提供
摘要：本发明属于药物化学技术领域，具体涉及2－(3－氰基－4－异丁氧基)苯基－4－甲基－5－噻唑甲酸(非布司他)的3种新晶型H、I、J及其制备方法，本发明进一步提供了此3种晶型的X－ray射线粉末衍射特征吸收峰和红外吸收峰，晶型的X射线粉末衍射图的反射角2θ在约为
6.71，
7.19，10.03，11.10，12.96，13.48，15.78，17.60和22.15°处有特征吸收峰。
本发明还涉及含有该新晶型的药物组合物以及该新晶型用于制造治疗尿酸过高有关的疾病的药物中的运用。
申请人：重庆医药工业研究院有限责任公司
地址：400061 重庆市南岸区涂山路565号
国籍：CN
更多信息请下载全文后查看。
不同商品规格温厚中厚朴酚与和厚朴酚的含量测定_冯劼
中华中医药学刊不同商品规格温厚中厚朴酚与和厚朴酚的含量测定冯劼1，吴晓宁2，3，余陈欢3，方杰3（1．杭州市红十字会医院，浙江杭州310003；2．浙江医学高等专科学校，浙江杭州310053；3．浙江中医药大学，浙江杭州310053）摘要：目的：建立不同商品规格温朴中厚朴酚与和厚朴酚含量的高效液相测定方法，测定不同商品规格温朴药材中厚朴酚与和厚朴酚的含量。
方法：色谱柱Hypersil BDS C18（250mmˑ4．6mm，5μm），流动相为甲醇－水（80ʒ20）。
结果：厚朴酚在0．45 230μg/mL，和厚朴酚在0．90 110μg/mL范围内线性关系良好。
含量测定结果表明，不同商品规格温朴药材中厚朴酚与和厚朴酚含量存在差异。
结论：不同规格温朴的内在质量有明显差异。
关键词：温朴；厚朴酚；和厚朴酚；HPLC法；含量测定中图分类号：R285文献标识码：A文章编号：1673－7717（2011）06－1338－02Determination of Honokiol and Magnolol in Different Specifications ofMagnolia Officinalis by HPLCFENG Jie1，WU Xiao-ning2，3，YU Chen-huan3，FANG Jie3（1．Hangzhou Red Cross Hospital，Hangzhou310003，Zhejiang，China；2．Zhejiang Medical College，Hangzhou310053，Zhejiang，China；3．Zhejiang Chinese Medical University，Hangzhou310053，Zhejiang，China）Abstract：Objective：To determine quantitatively the content of honokiol and magnolol in different specifications ofMagnolia officinalis．Methods：Chromatograp column Hypersil BDS C18（250mmˑ4．6mm，5μm）was used，mobile phase was methanol：water（80ʒ20）．Result：The linear range of honokiol and magnolol were0．45 230μg/mL，0．90 110μg/mL，respectively．The contents of honokiol and magnolol were different obviously in different specifications of sam-ples．Conclusion：There were significantly differences in intrinsic quality of Magnolia officinalis．Key words：Magnolia officinalis Rehd．et Wils．var biloba Rehd．et wils．；Honokiol；Magnolol；HPLC；Determination收稿日期：2010－12－29基金项目：浙江省中医药科学研究基金计划项目（2010ZB021）；浙江省大学生科技创新项目（67401140）作者简介：冯劼（1977－），男，浙江杭州人，主管中药师，学士，研究方向：中药有效成分分析及药效研究。